Chronic Obstructive Pulmonary Diseases:Journal of the COPD Foundation

Articles in Press

Peer-reviewed, accepted articles are posted in Articles in Press shortly after editorial acceptance. These posted articles (below) have completed a rigorous peer review process but the articles have NOT been copyedited or designed. Copyedited, designed, final versions of these articles will be created and published in a Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) upcoming issue. Articles in Press citations/abstracts are submitted to PubMed.

To receive notifications of the posting of new Articles in Press AND the posting of new JCOPDF issues, sign up for a FREE SUBSCRIPTION HERE.

Normal Routine Spirometry Can Mask COPD and Emphysema in Symptomatic Smokers

Arthur F. Gelb, MD1 Alfred Yamamoto, MD2 Eric K. Verbeken, MD3 James C. Hogg, MD, PhD4 Donald P. Tashkin, MD5 Diem N. T. Tran, BA6 Roxanna M. Moridzadeh, BA, PA-C6 Christine Fraser, CPFT, RT6 Mark J. Schein, MD7 Marc Decramer, MD, PhD8 Eric F. Glassy, MD9 Jay A. Nadel, MD10

Citation: Gelb AF, Yamamoto A, Verbeken EK, et al. Normal routine spirometry can mask COPD and emphysema in symptomatic smokers. Chronic Obstr Pulm Dis. 2020; Published online December 11, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0176

View Pre-proof PDF

New Adopters of Telemedicine During the Coronavirus-19 Pandemic in Respondents to an Online Community Survey: The Case for Access to Remote Management Tools for Individuals with Chronic Obstructive Pulmonary Disease

Danielle M. Boyce, MPH1 Byron M. Thomashow, MD1,2 Jamie Sullivan, MPH1 Ruth Tal-Singer, PhD1

Citation: Boyce DM, Thomashow BM, Sullivan J, Tal-Singer R. New adopters of telemedicine during the coronavirus-19 pandemic in respondents to an online community survey: the case for access to remote management tools for individuals with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020; Published online December 8, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0181

View Pre-proof PDF

Palliative Care Referral in the Chronic Obstructive Pulmonary Disease Population

Connie Bradley, BSN, RN1 Rebekah Martin, BSN, RN1 Channa Porter, BSN, RN1 Kimberly Richardson, BSN, RN1 Andrea Stress, BSN, RN1 Jenna L. Tobin, BSN, RN1

Citation: Bradley C, Martin R, Porter C, Richardson K, Stress A, Tobin JL. Palliative care referral in the chronic obstructive pulmonary disease population. Chronic Obstr Pulm Dis. 2020; Published online December 8, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0195

View Pre-proof PDF

Progression of Emphysema and Small Airways Disease in Cigarette Smokers

Esther Pompe1 Camille M. Moore2 Firdaus A.A. Mohamed Hoesein3 Pim A. de Jong3 Jean-Paul Charbonnier4 MeiLan K. Han5 Steven M. Humphries6 Charles R. Hatt7 Craig J. Galbán8,9 Ed K. Silverman10,11 James D. Crapo12 George R. Washko11 Elisabeth A. Regan13 Barry Make12 Matthew Strand2 Jan-Willem J. Lammers1 Eva M. van Rikxoort4 David A. Lynch6 on behalf of the COPDGene investigators

Citation: Pompe E, Moore CM, Hoesein FAAM, et al for the COPDGene Investigators. Progression of emphysema and small airways disease in cigarette smokers. Chronic Obstr Pulm Dis. 2020; Published online December 2, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0140

View Pre-proof PDF

Improving Screening for Alpha-1 Antitrypsin Deficiency With Direct Testing in the Pulmonary Function Testing Laboratory

Samuel Gurevich, MD1,2 Andrew Daya, MD2 Cristiana Da Silva, RRT, BS2 Christine Girard, MD2 Franck Rahaghi, MD2

Citation: Gurevich S, Daya A, Da Silva C, Girard C, Rahaghi F. Improving screening for alpha-1 antitrypsin with direct testing in the pulmonary function testing laboratory. Chronic Obstr Pulm Dis. 2020; Published online December 2, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0179

View Pre-proof PDF

Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency

Daniel J. Smith1 Paul R. Ellis, MBChB1 Alice M. Turner, MRCP, PGCE (MedEd), PhD1,2

Citation: Smith DJ, Ellis PR, Turner AM. Exacerbations of lung disease in alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis. 2020; Published online November 25, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0173

View Pre-proof PDF

Corticosteroid Dosing and Glucose Levels in COPD Patients Are Not Associated with Increased Readmissions

Meghan McGraw, MD1 Heath D. White, DO, MS, FCCP1 Carl Boethel, MD, FCCP, FAASM1 Kiumars Zolfaghari, MS1 Angela Hochhalter, PhD1 Alejandro Arroliga, MD1

Citation: McGraw M, White HD, Boethel C, Zolfaghari K, Hochhalter A, Arroliga A. Corticosteroid dosing and glucose levels in COPD patients are not associated with increased readmissions. Chronic Obstr Pulm Dis. 2020; Published online November 25, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0172

View Pre-proof PDF

Impact of Proactive Integrated Care on Chronic Obstructive Pulmonary Disease

Patricia B. Koff, RRT, MEd1* Sung-joon Min, PhD2* Debora L. P. Diaz1 Tammie J. Freitag, RN, BSN1 Shannon S. James, RN, BSN1 Norbert F. Voelkel, MD1 Derek J. Linderman, MD1 Fernando Diaz del Valle, MD1 Jonathan K. Zakrajsek1 Richard K. Albert, MD1 Todd M. Bull, MD1 Arne Beck, PhD3 Thomas J. Stelzner, MD3 Debra P. Ritzwoller, PhD3 Christine M. Kveton, RRT3 Stephanie Carwin, RRT3 Moumita Ghosh, PhD4 Robert L. Keith, MD1, 5 John M. Westfall, MD6 R. William Vandivier, MD1

Citation: Koff KB, Min S, Diaz DLP, et al. Impact of proactive integrated care on chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020; Published online November 25, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0139

View Pre-proof PDF

Comprehensive and Collaborative Pharmacist Transitions of Care Service for Underserved Patients with Chronic Obstructive Pulmonary Disease

Jennifer Kim, PharmD, BCPS, BCACP1-3 Amy Lin, PharmD4 Randy Absher, PharmD, BCPS1 Tanya Makhlouf, PharmD1 Casey Wells, PharmD Candidate3

Citation: Kim J, Lin A, Absher R, Makhlouf T, Wells C. Comprehensive and collaborative pharmacist transitions of care service for underserved patients with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020: Published online November 25, 2020. doi: https://doi.org/10.15326/jcopdf.2019.0175

View Pre-proof PDF

Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study

Chelsea L. Edwards, PhD1 Alan G. Kaplan, MD, CCFP(EM)2,3,4 Barbara P. Yawn, MD, MSc, MSPH5,6 Janwillem W. H. Kocks, MD, PhD1,7,8 Lakmini Bulathsinhala, MPH1 Victoria A. Carter, BSc1 Ku-Lang Chang, MD9 Chester Fox, MD10,11 Gokul Gopalan, MD12 MeiLan K. Han, MD13 Maja Kruszyk, BEng1 Chantal E. Le Lievre, BPH1 Cathy Mahle, PhD, MBA12 Barry Make, MD14 Wilson D. Pace, MD10,15 Chris Price, LLB1 Asif Shaikh, MD, MPH12 Neil Skolnik, MD16,17 David B. Price, FRCGP1,7,18

Citation: Edwards CL, Kaplan AG, Yawn BP, et al. Development of the Advancing the Patient Experience in COPD registry: a modified Delphi study. Chronic Obstr Pulm Dis. 2020; Published online November 24, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0154

View Pre-proof PDF

Black Carbon Content in Airway Macrophages is Associated with Reduced CD80 Expression and Increased Exacerbations in Former Smokers With COPD

Vickram Tejwani1 Eric Moughames2 Karthik Suresh1 Shih-En Tang3 Laura G. Mair2 Karina Romero2 Nirupama Putcha1 Neil E. Alexis4 Han Woo1 Franco R. D’Alessio1** Nadia N. Hansel1

Citation: Tejwani V, Moughames E, Suresh K, et al. Black carbon content in airway macrophages is associated with reduced CD80 expression and increased exacerbations in former smokers with COPD. Chronic Obstr Pulm Dis. 2020; Published online November 6, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0170

View Pre-proof PDF

Expanding Post-discharge Readmission Metrics in Patients with Chronic Obstructive Pulmonary Disease

Laura C. Myers, MD, MPH1,2 Carlos Camargo, DrPH, MD3 Gabriel Escobar, MD1,2 Vincent X. Liu, MD1,2

Citation: Myers LC, Camargo C, Escobar G, Liu VX. Expanding post-discharge readmission metrics in patients with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020; Published online November 6, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0160

View Pre-proof PDF

InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions

Arnaud Bourdin, MD, PhD1 Gerard Criner, MD2 Gilles Devouassoux, MD, PhD3,4 Mark Dransfield, MD5 David M.G. Halpin, MD6 MeiLan K. Han, MD7 C. Elaine Jones, PhD8 Ravi Kalhan, MD9 Peter Lange, MD10,11 Sally Lettis, PhD12 David A. Lipson, MD13,14 David A. Lomas, MD15 José M. Echave-Sustaeta María-Tomé, MD16 Neil Martin, MD17,18 Fernando J. Martinez, MD19 Holly Quasny,8 Lynda Sail, MD20 Thomas M. Siler, MD, FCCP21 Dave Singh, MD22 Byron Thomashow, MD23 Henrik Watz, MD24 Robert Wise, MD25 Nicola A. Hanania, MD, MS26

Citation: Bourdin A, Criner G, Devouassouz G, et al. Informing the pathway of COPD treatment single-inhaler triple therapy (fluticasone furoate/ umeclidinium/ vilanterol) versus fluticasone furoate/vilanterol and umeclidinium /vilanterol in patients with COPD: analysis of the Western Europe and North America regions. Chronic Obstr Pulm Dis. 2020; Published online November 5, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0158

View Pre-proof PDF

Protocol Summary of the CAPTURE Validation in Primary Care Study

Barbara P. Yawn, MD1,2 Meilan Han, MD, MPH3 Barry M. Make, MD4 David Mannino, MD5 Randall W. Brown, MD6 C Meldrum3 Susan Murray, ScD7 Cathie Spino, ScD7 Jacqueline S. Bronicki, MLIS, CCRA7 Nancy Leidy, PhD8 Hazel Tapp, PhD9 Rowena J. Dolor, MD10 Min Joo, MD, MPH11 Lyndee Knox, PhD12 Linda Zittleman, MPH. MSPH13 Byron M. Thomashow, MD14 Fernando J. Martinez, MD15

Citation: Yawn B, Han M, Make BM, et al. Protocol summary of the CAPTURE validation in primary care study. Chronic Obstr Pulm Dis. 2020; Published online November 5, 2020. doi: https://doi.org/10.15326/jcopdf.2020.0155

View Pre-proof PDF

The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(mattawa)/Q0(ourém)

Judith Bellemare, PhD, MD1 Nathalie Gaudreault, BSc1 Kim Valette, MD1 Irene Belmonte, PhD2 Alexa Nuñez, MD2 Marc Miravitlles, MD2,3 François Maltais, MD1 Yohan Bossé, PhD1,4

Citation: Bellemare J, Gaudreault N, Valette K, et al. The clinical utility of determining the allelic background of mutations causing alpha-1 antitrypsin deficiency: the case with the null variant q0(mattawa)/q0(ourém). Chronic Obstr Pulm Dis. 2020; Published online November 2, 2020. doi: https://doi.org/10.15326/jcopdf.8.1.2020.0168

View Pre-proof PDF

Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial

John S. Kim, MD, MS1,2 Michael A. Thomashow, MD1,3 Natalie H. Yip, MD1 Kristin M. Burkart, MD, MSc1 Christian M. Lo Cascio, MD1 Daichi Shimbo, MD1 R. Graham Barr, MD, DrPH1,4

Citation: Kim JS, Thomashow MA, Yip NH, et al. Randomization to omega-3 fatty acid supplementation and endothelial function in COPD: the COD-FISH randomized controlled trial. Chronic Obstr Pulm Dis. 2020; Published online November 2, 2020. doi: https://doi.org/10.15326/jcopdf.8.1.2020.0132

View Pre-proof PDF

Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany

Melanie Schroeder, MSc1 Katie Hall, MPH2 Lina Eliasson, PhD, CPsychol2 Sophia Bracey, MSc3 Necdet B. Gunsoy, PhD4 Jake Macey, MSc3 Paul W. Jones, PhD5 Afisi S. Ismaila, PhD6,7

Citation: Schroeder M, Hall K, Eliasson L, et al. Treatment preferences of patients with chronic obstructive pulmonary disease: results from qualitative interviews and focus groups in the United Kingdom, United States, and Germany. Chronic Obstr Pulm Dis. 2020: Published online November 2, 2020. doi: https://doi.org/10.15326/jcopdf.8.1.2020.0131

View Pre-proof PDF

Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

Citation: Radmila Choate, PhD, MPH, David M. Mannino, MD, Kristen E. Holm, PhD, MPH, Tatsiana Beiko, MD, MSCR, Bonnie Boyd, BSN, Robert A. Sandhaus, MD, PhD

Citation: Choate R, Mannino DM, Holm KE, Beiko T, Boyd D, Sandhous RA. Home-based multicomponent intervention increases exercise activity and improves body mass index: results of a 5-year randomized trial among individuals with alpha-1 antitrypsin deficiency-associated lung disease. Chronic Obstr Pulm Dis. 2020;8(1): Published online October 30, 2020. doi: https://doi.org/10.15326/jcopdf.8.1.2020.0183

View Pre-proof PDF

Copyright 2021 by COPD Foundation Disclaimer| Privacy|

The COPD Foundation is a nonprofit, tax-exempt charitable organization under Section 501(c)(3) of the Internal Revenue Code.